APOE and liver dysplastic nodule: ApoE ε2 genotyping could significantly increase the risk of DN comparing with ε3 genotyping (OR = 2.22, 95% CI = 1.41–3.47, and P < 0.05), while ApoE ε4 genotyping may decrease the risk of DN comparing with ε3 genotyping (OR = 0.70, 95% CI = 0.50–0.97, and P < 0.05).